Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study
Main finding · Hospitalisation or deathResult — go to the resultAdjusted odds ratio 0.12 95% CI 0.05–0.25Authors' conclusion
Outpatient treatment was associated with lower odds of severe COVID-19 outcomes compared with no outpatient treatment.
Study context
- Population
- Patients aged 18 years or older with a pre-existing systemic autoimmune rheumatic disease and COVID-19 onset between Jan 23 and May 30, 2022, Mass General Brigham, Boston, MA, USA347 [49%] with RA
- Participants
- 704 patients
- Exposure
- Outpatient SARS-CoV-2 treatment vs no outpatient treatment
- Outpatient treatmentn = 426
- No outpatient treatmentn = 278reference
- Outcome
- Severe COVID-19: hospitalisation or death within 30 days after the index date
- Follow-up
- 30 days
Methodological detailsmultivariable logistic regression
- Multivariable logistic regression
Main finding
Hospitalisation or death
Adjusted odds ratio
0.12
95% CI 0.05–0.25
Events by group
Outpatient treatmentvs No outpatient treatment
aOR 0.12 (95% CI 0.05–0.25)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Documented COVID-19 rebound after oral outpatient treatment | Oral outpatient treatment 7.9% |
- Documented COVID-19 rebound after oral outpatient treatment: 318 patients received oral outpatient treatment
Temporal trend in outpatient SARS-CoV-2 treatment
- Outpatient treatments increased in frequency over calendar time
- P < 0.0001
Original publication
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study. Lancet Rheumatol. Published 23 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →